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Abstract: Coronavirus disease 2019 (COVID-19) pandemic has been an important global interest that affected millions of people, and
it requires a deep investigation of the disease immunology for developing further therapeutic applications. Adoptive T cell therapy
promises to address T cell-dependent immune dysregulation in COVID-19 patients by the generation of specific T cell clones against
virus-specific antigens. Additionally, targeting B cell-dependent protection through COVID-19 vaccines, which have been developed
in the recent year, possessed sufficient prevention for spreading the virus, since the cases and deaths related to COVID-19 tend to
decrease after the vaccination. However, adoptive cell therapies are now encouraging scientists to deal with pathological challenges like
inadequate T cell-dependent immune response or lymphopenia, since they are the most frequent outcome of severe infection, especially
in immunocompromized patients. In this review, the current knowledge of immunopathology of COVID-19 was aimed to be highlighted
along with the T cell responses against SARS-CoV-2 to comprise a basis for therapeutics. Moreover, current therapeutics and treatment
strategies for COVID-19 were discussed to evaluate possible agents. Furthermore, the use of adoptive T cell therapy representing an
emerging therapeutic approach was purposed to be presented comprehensively against SARS-CoV-2 infection. Even though further
studies are needed to fully understand T cell response against SARS-CoV-2 in order to develop therapies to provide long term and
efficient protection, adoptive cell therapies now meet the demand for a large population of people who suffer immunocompromization,
considering the previous usage of the technique for different infectious diseases.
Key words: Adoptive cell therapy, COVID-19, immunotherapy, SARS-CoV-2, T cell response

1. Introduction
Coronavirus disease 2019 (COVID-19) has become the
biggest burden to the world in terms of health and economy
as the third coronavirus outbreak of the 21st century
because of a positive sense, single-stranded RNA virus
called Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2) was detected in over 249 million confirmed
cases worldwide as of November 9, 2021. The disease was
firstly raised in the city of Wuhan in China in December
2019, and the number of deaths caused by the tremendous
spread of the virus hit 5 million all over the world
according to the data of the World Health Organization
(WHO) (World Health Organization, 2021).
The virus has now been circulated massively around
the world through human-to-human contact and became
a big burden to healthcare professionals (Kumar and Al
Khodor, 2020). Infected patients developed very critical

diseases and poor clinical outcomes including respiratory
failure, fever, cough, systemic shock, multi-organ failure,
and acute respiratory distress syndrome (ARDS) with
severe pneumonia and need in-patient care and mechanical
ventilation (Blanco-Melo et al., 2020; Kumar and Al
Khodor, 2020). The severe inflammation in response to
SARS-CoV-2 has been observed mainly in critical cases,
which is presumably the most involved mechanism for
the pathogenesis of COVID-19 including an excessive
amount of inflammatory cytokine and chemokine release,
prolonged and serious lymphopenia, and tissue infiltration
of inflammatory cells (Sengupta, 2020). Several vaccines
developed with different techniques are now encouraging
scientists; however, further investigation is required for
people who need treatment for ongoing SARS-CoV-2
infection, since vaccines are only effective for SARSCoV-2-negative individuals. Therefore, revealing the
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pathophysiology and the underlying mechanisms of
COVID-19 are of high importance in terms of developing
new treatment strategies like antiviral drugs, effective
vaccine candidates, and inhibitors targeting both viral
spike proteins and host receptors. Among those strategies,
focusing on the main concern in severe cases about
the mechanism of clearance of the infection, which is
employed fundamentally by T cells, could be a rational
approach by implementing adoptive T cell therapy.
2. Pathophysiology and clinical presentation of
COVID-19
The infection of the airborne virus SARS-CoV-2 occurs via
droplets or contacts that mediate virus entry to the body
and ultimately to cells (Parasher, 2020; Chee et al., 2021).
Betacoronaviruses utilize this cell entry mechanism, which
is a fundamental element for interspecies transmission,
through their surface spike glycoprotein binding to the
receptor of the transmitted cell (Zhao et al., 2020;To et al.,
2021). The spike glycoprotein is a trimer projecting out of
the virus and involves two subunits, in which recognition
and binding take place, the S1 subunit, and cleavage, and
release the spike fusion protein through the S2 (Kumar
and Al Khodor, 2020; Parasher, 2020; Sardar et al., 2020;
Sridhar and Nicholls, 2021; To et al., 2021). As Middle East
Respiratory Syndrome Coronavirus (MERS-CoV) enters its
target cell via the dipeptidyl peptidase-4 (DPP4) receptor,
SARS-CoV and SARS-CoV-2 both have a cell entering
machinery through binding angiotensin-converting
enzyme 2 (ACE2), which is the most characterized
receptor for these viruses (Letko et al., 2020; Millet et
al., 2021). The spike protein, which all betacoronaviruses
encode, contains a very specific region known as the
receptor-binding domain (RBD) that binds to the cell
receptor of the host and mediates viruses to enter the cell
(Crooke et al., 2020). Following attachment of the RBD of
spike protein on the S1 subunit to its receptor ACE2, viral
entry involves the cleavage of spike protein with the host
transmembrane protease serine 2 (TMPRSS2) so that the
fusion peptide releases from the S2 subdomain, and the
virus enters the cell by endocytosis (Johansen et al., 2020;
Kumar and Al Khodor, 2020; Parasher, 2020; Wiersinga et
al., 2020; Zhu et al., 2020).
ACE2 is a well-defined integral membrane
metalloproteinase involving in the renin-angiotensinaldosterone system (RAAS) and is highly abundant
throughout the body (Barker and Parkkila, 2020;
Bourgonje et al., 2020; Tas et al., 2020; Tay et al., 2020).
Both ACE2 and TMPRSS2 are especially present on
targeted alveolar epithelial type 2 cells in the human body
(Wiersinga et al., 2020). Although ACE2 expressing cells
can mainly facilitate cell entry for the virus, the revealed
pathophysiological mechanisms of COVID-19 represent
that not all organs share the same infection state and
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outcome, which may be due to different parameters
affecting the receptor expression, disease severity, and
progress (Bourgonje et al., 2020; Tas et al., 2020; Wiersinga
et al., 2020).
ACE2 expression is the most abundant in type 2
alveolar cells, epithelial cells of the intestine, vascular
endothelial cells, cardiac cells, and proximal tubular cells
of the kidney (Bourgonje et al., 2020; Tas et al., 2020). Even
though lungs are the main concern in COVID-19 patients,
clinical outcomes showed that patients face serious tissue
damages in their hearts and kidney as well (Bourgonje et
al., 2020). The acquired virus through respiratory aerosols
attaches to upper respiratory tract nasal epithelial cells
where ACE2 is abundantly present. During the first few
days, on-site replication and eventually a rapid increase in
virus population occurs as well as increasing transmission
through ciliated cells of airway epithelium. Reported
cases predominantly do not develop further stages of
the infection, as the immune response is qualified to
control the propagated virus (Parasher, 2020; Stratton et
al., 2021). However, progressing infection throughout
alveolar epithelial type 2 cells of the lower respiratory
tract becomes the Achilles heel for the immune system,
as substantive immune response fails to exist, resulting in
excessive cytokine and inflammatory components release
from pneumocytes (Parasher, 2020; Chee et al., 2021;
Sridhar and Nicholls, 2021). This trafficking of cytokines
and chemokines attracts neutrophils, CD4+ T cells, and
CD8+ T cells to the lung tissue in which gradually growing
inflammation and tissue damage adds a greater complexity.
The widespread alveolar damage emerges ultimately
resulting in an ARDS related to chronic depredation
caused by the accumulating cells and viral replication
generating serious damage on type 2 as well as type 1
pneumocytes (Mathew et al., 2020; Parasher, 2020; Tay
et al., 2020; Neurath, 2021; Sridhar and Nicholls, 2021;
Stratton et al., 2021).
Within COVID-19 patients, prolonged inflammation
against the virus is considered to be a remarkable factor
for the progression of the disease and mortality, and it
is associated with the elevated degree of cytokines in
circulation, extreme lymphopenia, and severe penetration
of mononuclear cells into the lungs, heart, kidneys,
spleen and lymph nodes as well as significantly increased
C-reactive protein (CRP), Pentraxin-3, serum ferritin, and
D-Dimers (Felsenstein et al., 2020; Harrison et al., 2020;
Merad and Martin, 2020; Brunetta et al., 2021; Genc AB
et al., 2021).
3. T cell response in COVID-19
T cell immunity in COVID-19 remains under deep
investigation (Luo et al., 2020; Mathew et al., 2020; Rodda
et al., 2021; Toor et al., 2021) because viral infections
require efficient T cell responses for complete clearance and
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long-term protection against viruses (Nelde et al., 2020;
Agerer et al., 2021; Jarjour et al., 2021). Immune defense is
initiated firstly through innate immune recognition finally
leading to the stimulation of adaptive immune response,
while the disease progresses and ultimately increases
leukocyte activation (Dai et al., 2021; Rha et al., 2021;
Sette and Crotty, 2021). The crucial step in the lymphocyte
activation is the presentation of antigens by antigenpresenting cells (APCs) such as monocytes, macrophages,
and dendritic cells that drive the induction of T cells and
B cells leading to the elimination of infected cells by CD8+
T cells and generation of humoral response by B cells
(Gujar et al., 2020; Dai et al., 2021; Rodda et al., 2021).
Acknowledging the effector functions, follicular helper
CD4+ T (Tfh) cells employ priming of B lymphocytes in
order to generate high-affinity virus-specific neutralizing
antibodies; besides, CD4+ T cells help CD8+ T cells to
respond to chronic infections consequentially by producing
IL-21, which is a cytokine of Tfh cells (Tay et al., 2020;
Laidlaw et al., 2016; Cui et al., 2021; Jarjour et al., 2021;
Sette and Crotty, 2021). Also, to promote the induction of
the immune cells to the environment where the infection
occurs, differentiated distinct subpopulations of CD4+ T
helper (Th) cells are needed for cytokine production such
as Th1, Th2, and Th17 cells (Swadling and Maini, 2020; Tay
et al., 2020; de Candia et al., 2021; Sette and Crotty, 2021).
Mainly, CD8+ T cells are necessary to attack and
destroy the infected cells directly by generating an antigen
recognition against virus antigens presented on major
histocompatibility complex (MHC) class-I molecules found
on the infected cell surface (Swadling and Maini, 2020;
Bertoletti et al., 2021; Rha et al., 2021; Toor et al., 2021).
Cytotoxic molecules, including granzyme B, perforin, and
IFN-γ are released by CD8+ T cells, and infected cells
are eliminated through downstream mechanisms and
pathways (Luo et al., 2020; Swadling and Maini, 2020;
Toor et al., 2021). Finally, that recognition leads to the
specialization and generation of immunological memory
(Gujar et al., 2020; Tay et al., 2020; Bertoletti et al., 2021;
Jarjour et al., 2021; Rodda et al., 2021). Furthermore,
virus-derived peptide presentation to CD4+ T helper
cells is executed by professional APCs through MHC
class-II molecules once viral antigens are picked up from
their surroundings and processed by APCs (Bertoletti
et al., 2021; de Candia et al., 2021). Th cells polarize
predominantly in the direction of Th1 when Th cells are
subjected to the antigen presentation, resulting in the
generation of IFN-γ and associated cytokines to remove
the virus (Sette and Crotty, 2021; Toor et al., 2021).
There seems to be a significant confusion as to whether
adaptive immune responses to SARS-CoV-2 are defensive
or pathogenic, although both outcomes have been revealed
since the beginning of the infection depending on the
duration, structure, or degree of the adaptive immune

response (Chen and John Wherry, 2020; Grifoni et al., 2020;
Mathew et al., 2020). In the respiratory tract and other
tissues, autopsies also showed elevated levels of SARSCoV-2, indicating inadequate immune responses (Chen
and John Wherry, 2020; Mathew et al., 2020). Furthermore,
few reports demonstrated that an overstimulated immunity
contributes to the pathophysiological outcome in which
possible mechanisms have been mostly associated with
exhaustion or impairment of T cells in the patients failing
viral clearance (Mathew et al., 2020; Nelde et al., 2020;
Rha et al., 2021; Toor et al., 2021). Nevertheless, it is still
not clearly defined that immunopathology is observed
because of whether over-activation or suppression of the
adaptive immune response in serious cases of the SARSCoV-2 infection (Agerer et al., 2021; de Candia et al., 2021;
Jarjour et al., 2021; Toor et al., 2021). Correspondingly,
both hyperactivation or exhaustion of T cells in patients
with COVID-19 has been seen in several studies (Diao
et al., 2020; Fathi and Rezaei, 2020; Mathew et al., 2020;
Weiskopf et al., 2020; Rha et al., 2021; Toor et al., 2021).
To induce an adequate immune response, a defensive
primary T cell response against SARS-CoV-2 infection
involves the recruitment and activation of antigen-specific
naïve CD4+ T cells and CD8+ T cells followed by expanding
the cell population rapidly and differentiating into
appropriate effector cell types (Jarjour et al., 2021). Most
of the studies showed that T cells detect structural proteins
of SARS-CoV-2 predominantly, notably spike, membrane,
and nucleocapsid proteins. They appear to evoke a robust
T-cell response in both symptomatic and asymptomatic
people, and, therefore, analysis demonstrated that they
are immunogenic for both CD4+ T cells and CD8+ T cells
(Rydyznski Moderbacher C et al., 2020; Bertoletti et al.,
2021; Bilich et al., 2021; Le Bert N et al., 2021).
SARS-CoV-2-specific CD4+ T cells showed a greater
correlation with reduced severity of COVID-19 than
antibodies and CD8+ T cells, while successful generation of
SARS-CoV-2-specific CD4+ T cells at the early onset of the
COVID-19 was correlated with increased viral clearance
and, thus, moderate the disease (Rydyznski Moderbacher
C et al., 2020; Sette and Crotty, 2021). Differentiation of
SARS-CoV-2-specific CD4+ T cells into Th1 and Tfh cells
in response to SARS-CoV-2 has been observed, and SARSCoV-2 specific circulating Tfh cells, which are responsible
for the generation of virus-specific neutralizing antibody
response, and memory B cells were found to be accelerated
in the acute phase of COVID-19 (Rydyznski Moderbacher
C et al., 2020; de Candia et al., 2021; Jarjour et al., 2021;
Sette and Crotty, 2021). On the other hand, the generation
of Th2, Th17, and regulatory T cells from CD4+ T cells
was associated with increasing disease severity according
to CD8+ T cell exhaustion (Rydyznski Moderbacher C et
al., 2020; Bertoletti et al., 2021; Jarjour et al., 2021; Sette
and Crotty, 2021).
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Prolonged T cell exhaustion is the characteristic
of COVID-19, culminating in progressive immune
deficiency, coinfection, and death as well. In a study that
was conducted with 3 COVID-19 cases, bone marrow
hypoplasia and reduced lymphocyte levels, degenerative
changes, and necrosis of the spleen cell were pathologically
observed (Luo et al., 2020; Yao et al., 2020). The depletion
of T cells can be induced by either T cell hyperactivation
or overexpression of proapoptotic proteins (eg, FAS or
TRAIL) (Esmaeilzadeh and Elahi, 2021). T cell counts
have steadily recovered the values similar to mild cases
of patients suffering severe COVID-19 (Luo et al., 2020).
The most important mechanism, which is developed
in COVID-19 patients following therapy, is immune
restoration, marked by an elevation in the number of
T cells. Improving immune reconstruction, especially
COVID-19 specific T cells, is, therefore, a significant
research field (Luo et al., 2020).
Increased virus-infected cells contribute to tissue
destruction and more fatal implications are compromised
by viral progenies (Luo et al., 2020; Toor et al., 2021). CD4+
T cells and CD8+ T cells struggle to have sufficient cellular
immune response followed by an insufficient humoral
response to remove virus-infected cells under the conditions
where the first line of defense was failed (Altmann and
Boyton, 2020; Swadling and Maini, 2020; Toor et al., 2021).
Nonetheless, priming of Th cells for the phenotype of Th17
is dominated under these circumstances, resulting in the
suppressed immune responses mediated by Th1 in which
cytokines derived from Th17 have been involved in the
severe lung pathophysiology found in cases with ARDS
by this way of suppression (Luo et al., 2020; Esmaeilzadeh
and Elahi, 2021; Patel et al., 2021; Rodda et al., 2021; Toor
et al., 2021). Cytokine production, particularly TNF-α, IL1β, IL-2, IL-6, and IL-10, is elevated in extreme COVID-19
conditions, contributing to cytokine release syndrome
formation, which causes more unfavorable outcomes and
can ultimately lead to lymphopenia (Altmann and Boyton,
2020; Fathi and Rezaei, 2020; Luo et al., 2020; Mathew et
al., 2020; Weiskopf et al., 2020; Patel et al., 2021; Toor et al.,
2021). In COVID-19 cases, lymphopenia is an expected
pattern, especially in elder people, which may be a crucial
feature relevant to the seriousness of the disease and
mortality (Luo et al., 2020). Targeted depletion of natural
killer (NK) cells together with both CD4+ T cells and
CD8+ T cells are observed in lymphopenia, and activation
of T cells and elevated expression of inhibitory T cell
receptors are exceedingly notable in severe cases than in
moderate ones (Song et al., 2020; Toor et al., 2021). A large
number of cytotoxic molecules are released from CD8+ T
cells in patients with severe cases; however, the reason for
lymphopenia is still unclear (Fathi and Rezaei, 2020; Song
et al., 2020).
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Formation of memory T cell response is required for
prolonging protection against SARS-CoV-2, dependent
on the generation of memory CD4+ T cells, which are
essential for the induction of B cells and CD8+ T cells
(Jarjour et al., 2021). Although recent studies revealed
that SARS-CoV-2 specific T cell memory lasts longer than
B cell memory, cross-reactive T cell responses constitute
a relatively important section of the defense later on the
possible intercourse with the virus (Agerer et al., 2021;
Bilich et al., 2021; DiPiazza et al., 2021). Besides all, there
has been a great deal of interest in the possibility of T cell
cross-reactivity between human circulating common cold
coronaviruses (229E, NL63, HKU1, and OC43) and SARSCoV-2. Cross-reactive T cells that are already present in
the body have the potential to accelerate viral elimination
and enhance patient outcomes after infection (DiPiazza et
al., 2021).
T cell immunity preserves its place as the most
important line of response against SARS-CoV-2, especially
for people who are failed to develop seroconversion and
immunocompromized patients who have a lower possibility
of developing an efficient antibody response (Gallagher et
al., 2021). One study showed that IgG antibody titers can
be prolonged up to one year after SARS-CoV-2 infection
in which severe cases have even higher antibody titers
through twelve months than nonsevere cases, yet gradually
decreasing of IgG titers have been observed for the first
six months up to 70% for all cases and twelve months up
to 88% (Xiao et al., 2021). In the past few months, some
studies evaluated the prolongation and protection status
of antibody immune responses after vaccination, though
several vaccine studies already revealed that antibody
titers show a tendency to drop in 3 months after two doses
of vaccination with RNA vaccine (BNT162b2) (Favresse
et al., 2021). Scientists have been now considering booster
shots to increase the antibody titers provided by the
vaccines because antibody levels tend to decrease after the
first two shots (Urbanowicz et al., 2021). While one study
showed that a third dose of RNA vaccine (BNT162b2) as
a booster increased the neutralizing antibody titers in the
patients after two doses, another study with the inactive
vaccine or recombinant RBD protein vaccine did not
induce a boosting after two doses of inactive vaccine, and
an adenovirus vaccine used as a booster showed induced
higher T cell response (Zhang et al., 2021). Even though
vaccine studies are still ongoing, other crucial factors alter
the effect of antibody responses generated by vaccines such
as the SARS-CoV-2 variant of concerns, which finally raise
the question of whether humoral immunity could provide
adequate long-term protection by natural immunization
or vaccination (Bertoletti et al., 2021; Souza et al., 2021;
Tauzin et al., 2021). The possible answer could be no, even
though further studies are required for both B cells and
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T cells in which generation of adequate B cell response
and memory formation is functionally dependent on the
generation of adequate T cell response by whether natural
infection or vaccination. Therefore, focusing on T cell
response rather than humoral response would change
the direction of the pandemic positively in terms of the
generation of new therapeutics.
4. Current therapeutics and adoptive T‐cell therapies
against COVID‐19
Current scientific studies predominantly focused on
vaccine development for COVID-19 in order to prevent
the spread of the infection and reduce the severity of the
disease. Therefore, COVID-19 vaccines preserve their
places as defensive measures in the health care system
for uninfected patients although wide-spreading SARSCoV-2 variant of concerns (VOCs) constitute several
challenges concerning the protective level of the vaccines
in terms of immune evasion (Edara et al., 2021; GarciaBeltran et al., 2021; Shen et al., 2021; Wang P. et al., 2021b;
Wang Z. et al., 2021). Moreover, Bates et al. (2021) revealed
that age-dependent reduction was detected in neutralizing
antibody titers of people who received two doses of
BNT162b2 vaccine against the USA-WA1/2020 strain and
the P.1 variant of concern (Bates et al., 2021). Also, the
duration of the protection provided after infection or by
vaccination could be insufficient to predict the long-term
immunity yet and arise the questions for postvaccination
that focused on whether people need vaccination at regular
intervals (Bilich et al., 2021; Dan et al., 2021; Edara et al.,
2021; Eyre et al., 2021; Gerhards et al., 2021; Goel et al.,
2021; Knies et al., 2021; Wang Z et al., 2021) While further
vaccine research has been considered for protection of
people who have no existing infection, treatment strategies
are on demand for those people with ongoing SARSCoV-2 infection (Gavriatopoulou et al., 2020; Kaplon and
Reichert, 2021; Phan et al., 2021).
Commonly used strategies for COVID-19 treatment
focus on neutralizing the viral material using convalescent
plasma or therapeutic monoclonal antibodies (mAbs),
virus-host interaction blockers, replication and
transcription complex blockers, and immunomodulators
(Gavriatopoulou et al., 2020; Woo, 2021). Neutralizing
mAb treatment is now encouraging scientists to treat
infected patients although SARS-CoV-2 variants still
possess an important line of obstacles (Wang P. et al., 2021a,
2021b). Nevertheless, none of the ongoing treatment
options focus on the major challenge faced by the failure
of the immune system during SARS-CoV-2 infection
(Gavriatopoulou et al., 2020; Monzavi et al., 2021). In order
to generate a long-term immunity and prime the effector
cells that actually can clear the infection and possess a
memory for the future, adoptive cell therapy (ACT) meets
the demand for people who suffer failed conventional

COVID-19 therapy because of a certain condition such
as cancer, immunocompromizing, or old age (Keller
et al., 2020; Bertoletti and Tan, 2020; Chan et al., 2021;
Ferreras et al., 2021; Monzavi et al., 2021; Zmievskaya et
al., 2021). As it is seen in the previously described study
that measures the neutralizing antibody titers of people
with USA-WA1/2020 strain and the P.1 variant of concern
who received two doses of BNT162b2 vaccine, vaccineinduced neutralization antibody titer against SARS-CoV-2
decreased in an age-dependent manner.
While ACT already has been a popular method in
the production of cancer therapies during the twentyfirst century, viral infections have been attracted a great
deal of attention to generating virus-specific T cells using
ACT strategies (Gujar et al., 2020; MacKay et al., 2020;
Bachanova et al., 2020; Dai et al., 2021; Ferreras et al.,
2021). Recently, developing SARS-CoV-2-specific T celldependent therapies have gained a wide currency, since
inducing persistent immune response and memory have
been the main concern for COVID-19 (Keller et al., 2020;
Bilich et al., 2021; Chan et al., 2021; Ferreras et al., 2021).
Generation of virus-specific T cells mainly aims to
achieve destroying the infected cells by antigen-specific
CD8+ T cells that release cytotoxic granules, while antigenspecific CD4+ T cells are generally employed by prime
B cells to produce virus-specific antibodies as described
earlier. Moreover, ACT also aims to generate both CD8+ T
cells and CD4+ T cells secreting cytokines such as IFN-γ
and TNF-α/β that employ communicating other immune
system compartments during the viral infection (Bertoletti
and Tan, 2020; Keller et al., 2020; Bilich et al., 2021; Chan
et al., 2021; Ferreras et al., 2021).
There have been several approaches to generate virusspecific T cells in general. One strategy allows developing
antigen-specific T cells after priming them with APCs that
are previously loaded with virus-specific antigens (Figure
1A). Moreover, one clinical study, which is still in Phase
I/II clinical trial, has been conducted for COVID-19
in China (NCT04276896) that uses modified DCs
carrying COVID-19 targeted genes to generate activated
SARS-CoV-2 specific cytotoxic T cells for COVID-19
treatment (Gavriatopoulou et al., 2020; Monzavi et al.,
2021). Another approach is to generate virus-specific T
cells isolated from peripheral blood mononuclear cells
(PBMCs) of convalescent donors activated by using virusspecific peptides followed by enrichment of targeted T
cells by immunomagnetic cell sorting mostly based on
IFN-γ capturing (Figure 1B). Most of the ACT strategies
mainly focused on this type of immunotherapy for
COVID-19, since convalescent donors already possess
SARS-CoV-2-specific T cells (Keller et al., 2020; Leung et
al., 2020; Cooper et al., 2021; Ferreras et al., 2021; Monzavi
et al., 2021). Furthermore, genetic engineering methods
became popular for ACT to generate virus-specific T
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Figure 1. Schematic representation of autologous or allogeneic cell therapy to generate SARS-CoV-2-specific T cells using donorderived lymphocytes. (A) PBMCs from a healthy donor or candidate patient can be isolated for autologous cell therapy followed by
monocyte-derived dendritic cells (DC) generation by stimulating of monocytes in an appropriate media to induce DC differentiation.
SARS-CoV-2 peptide pool can be established using recombinant DNA technology for stimulation of immature autologous DCs ex vivo.
Coculturing of isolated T cells with peptide loaded DCs allows generation of T cells with specific T cell receptors (TCR) that recognize
viral antigens. Isolated and expanded virus-specific T (VST) cells could be used for patient with ongoing SARS-CoV-2 infection. (B)
COVID-19 convalescent donor-derived PBMCs can be cocultured in a feasible environment with SARS-CoV-2 peptide pool to generate
T cells specific to SARS-CoV-2 antigens for allogeneic cell therapy. Generation of activated VST cells is followed by isolation and
expansion for adoptive transfer of the VST cells.

cells by sequencing virus antigen-specific TCRs followed
by synthesis of the sequence and engineering the TCRs
utilizing the vector that contains the sequences (Hayes,
2020; Monzavi et al., 2021). By this method, T cells that
have specific TCRs target virus-specific antigens directly
are generated and expanded ex vivo to be used for patients
(Figure 2A).
Chimeric antigen receptor (CAR) T cells are one
of the preferred ones among ACTs in which there are
CAR-T cell immunotherapies approved by the Food
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and Drug Administration (FDA) for different diseases
including cancer, autoimmune diseases, and infectious
diseases (Seif et al., 2019; Haddadi et al., 2020; Hayes,
2020; Voelker, 2020). CARs are artificial structures
containing extracellular regions constituted from a singlechain variable fragment (scFv) of a mAb for target cell
detection, together with a part of the intracellular domain
for the activation of T cells (Dwivedi et al., 2019; Seif et
al., 2019; Monzavi et al., 2021; Zmievskaya et al., 2021).
CAR-T cells constitute a major advantage, as it does
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not require an MHC molecule for antigen recognition.
The multistep procedure for developing CAR-T cells
for implementation of immunotherapy starts with the
isolation of antigen-specific antibodies from the peripheral
blood of a convalescent patient, preceded by sequencing
of the protein to use it in engineering the sequences and
generating CAR vector in an scFv format followed by the
viral incorporation or nonviral fusion of CAR genes into
the nucleus of the T cells (Dwivedi et al., 2019; Seif et al.,
2019; Monzavi et al., 2021; Zmievskaya et al., 2021). Then,
the CAR-T cells are multiplied, and the patient is injected
with the cell substance (Figure 2B). The major objective

of CD8+ T cells is the potential capacity to remove cells
and factors that are detected as foreign items and to treat
infectious diseases by allowing those cells as favorable
CAR-T (Dwivedi et al., 2019; Seif et al., 2019; Chan et al.,
2021; Tay et al., 2020). Recently, the method based on the
employment of transduced CAR immune cells, as opposed
to virus-infected cells, has drawn a scientific interest as an
immunotherapeutic approach for COVID-19 (Mathew et
al., 2020; Esmaeilzadeh and Elahi, 2021; Monzavi et al.,
2021; Zmievskaya et al., 2021).
In addition to the growing variety of therapeutic uses,
knowledge acquired from CAR-T cell immunotherapy

Figure 2. Schematic representation of virus-specific transgenic TCR-T cell and CAR-T cell generation for adoptive cell therapy. (A)
Isolated T cells from either autologous or allogeneic donors can be genetically engineered using gene vectors encoding virus antigenspecific TCR (B) or virus antigen-specific CAR followed by stimulation of the cells for expanding the cell count of transgenic TCR-T
cells or CAR-T cells ex vivo to be used for patients.
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has enabled scientists to overcome other complications
of the disease. The cytokine release syndrome triggered
by proinflammatory cytokine over-secretion (e.g., IL-6 or
IFNγ) through CAR-T cells stimulated responding infected
cell recognition is an important indication (Vardhana
and Wolchok, 2020; Zmievskaya et al., 2021). Last but
not the least, cytokine release syndrome, characterized
by effects such as fever, fatigue, hypoxia, muscle pain,
hypotension, and dysfunction in the kidney, is a significant
undesirable effect of CAR-T cell therapy (Zmievskaya et
al., 2021). Scientific studies are ongoing to overcome those
disadvantages, yet enhancement of the method opens the
way of treatment options for different diseases and gives
rise to developing new strategies for especially emerging
infections like COVID-19.
In immunocompromized people, adoptive transferring
of virus-specific CD8+ T cells in which cells are derived
from donors has proven effective for the management of
many different infectious diseases. Yet, some difficulties
still exist for adoptive T-cell therapy. Firstly, it is impossible
to use allogeneic T cells from unrelated people because
of hereditary limitations caused by Human Leukocyte
Antigen (HLA) class I, yet the usage is limited to donorderived T cells and challenges remain for large-scale
manufacturing. To this end, graft-versus-host disease
(GvHD) might be a significant risk factor for COVID-19
patients after the transfer, thereby suggesting engineered
donor-derived cells and banking of HLA- matched
lymphocytes may resolve the issue (Cooper et al., 2021;
Ferreras et al., 2021; Monzavi et al., 2021). Moreover, by
sustained treatment with a particular virus antigen, donor
T cells are extended in the culture to obtain an adequate
amount of effector T cells to be permeated (Caccamo et al.,
2020; Esmaeilzadeh and Elahi, 2021; Monzavi et al., 2021).
In cases where CD8+ T cells are depleted and struggling
for proliferation and expansion, this is a significant
obstacle, as it happens in COVID-19 patients, where
the amount of peripheral blood CD8+ T cells is deeply
decreased, and CD8+ T cells are functionally depleted.
Despite the decreased cell count, aberrant activation of
CD8+ T cells is seen and appears to be related to disease
severeness. Thus, adoptive transferring of those aberrant
cells might raise the aggressiveness and cause damage
especially around the lymphocyte-infiltrated lung tissue
(Song et al., 2020; Monzavi et al., 2021). Engineering T
cells for regulating activation and suppression by creating
on-off switches as described in Ellis et al. may increase
the efficacy of treatment strategies, but it is not widely
applicable for patients with comorbidities such as cancer
(Basar et al., 2020; Ellis et al., 2021). Lastly, the so-called
“cytokine release syndrome” is a significant side effect of
T-cell therapies, a substantial inflammatory reaction that
leads to ARDS and multiple organ failure in the patients. A
similar condition is also observed in COVID-19 patients,
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so the toxicity of the therapy would add further complexity
such as inflammatory syndromes (Basar et al., 2020, 2021;
Caccamo et al., 2020; Esmaeilzadeh and Elahi, 2021).
Besides all possible adverse effects of T-cell therapy
that would be seen in COVID-19 cases stated so far, the
promising approaches constitute considerable advantages.
The cells of human HLA-E-restricted CD8+ T cells have
antimicrobial and cytolytic behaviors. These CD8+ T
cells, however, also generate IL-4, IL-5, IL-13, and, to a
varying degree, IL-10 and TGF-β, in addition to the usual
Th1 cytokine IFN-γ (Caccamo et al., 2020; Vardhana and
Wolchok, 2020). One study proposes that the use of HLAE-restricted CD8+ T cells will give many benefits to patients
having COVID-19 to improve T-cell immunotherapy,
such as the combined ability to destroy infected cells and
prevent intracellular infections by minimizing the level
of the inflammatory response and reducing adjacent
tissue damage, of what is being considered as an essential
factor of the pathway (Caccamo et al., 2020; Vardhana
and Wolchok, 2020). Another significant feature is the
monomorphic antigen recognizing paradigm of HLAE-restricted CD8+ T cells, which enables the global
heterogeneous population to use them (Caccamo et al.,
2020). Also, HLA-E-restricted CD8+ T cells are unable to
build allogeneic reactions and induce phenomena of graftversus-host disease. In theory, HLA-E-restricted CD8+
T cells against SARS-CoV-2 can be affordable and easily
developed with donations of COVID-19 convalescent
allogeneic samples in large quantities, collected and used
when needed for serious COVID-19 cases (Caccamo et al.,
2020).
There is also a potential to extend the possible adoptive
cell therapeutics by addressing the clearance of the infected
cells as an alternative strategy to adoptive T-cell therapy.
Given the importance of NK cells as effector lymphocytes
of innate immunity, the killing tumor and virally infected
cells is a potential therapeutic strategy as well. When MHC
class I molecules decreased on the surface of the infected
cells, NK cells work by either specific identification of
virus-related proteins or inhibiting NK receptor signaling.
(Golchin, 2020; Zmievskaya et al., 2021).
In brief, using SARS-CoV-2-specific T cells appears to
be a reasonable therapeutic approach to treat COVID-19
depending on the adoptive T-cell therapy background in
multiple pathological conditions, involving viral infections.
Either autologous or allogeneic T cells specific to the
virus can be expanded in vitro and administrated to the
patient to reconstruct a successful immunity against the
virus, and they have provided successful outcomes to treat
several viral infections. SARS-CoV-2-specific T cells could
be separated and extended using SARS-CoV-2-derived
proteins from the bloodstream of convalescent donors and
exploited for the treatment of serious COVID-19 cases
(Toor et al., 2021). Since using this method for COVID-19
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is currently not that common, there is poor knowledge
about the effectiveness, toxicities caused by the therapy,
and difficulties for using the adoptive T‐cell therapy.
Significantly, because of genetic limitations (HLA class I),
it is not feasible to use incompatible allogeneic T cells, and
in vitro expanded T cells could display functional depletion
by sustained stimulation to attain necessary cell counts,
or transferred T cells could generate cytokine release
syndrome, contributing to COVID-19 disease difficulties
(Toor et al., 2021). A continuing clinical trial based on
preliminary adoptive T-cell therapy for COVID-19 exists,
while another prospective clinical trial would follow an
innovative solution using SARS-CoV-2-specific T cells
from recovered COVID-19 patients for treating patients
with elevated respiratory failure (Caccamo et al., 2020;
Toor et al., 2021).
5. Conclusion
T cell-dependent immune dysregulation has become
a major problem in COVID-19 patients leading to an
accelerated disease severity depending on the inability of
the immune system to defend the body, rapid spread of
the virus, and increased anti-inflammatory response. As
a matter of fact, elder people or immunocompromized
patients who are suffering from different diseases already
possess a lower amount of naïve T cells to make an adequate
adaptive immune response to a newly occurred infection
such as COVID-19. Therefore, adoptive T-cell therapy
is a promising treatment option for those patients who
struggle to have a T cell response and neutralizing antibody
response depending on the inadequate T cell activation or
the lack of enough amount of naïve T cells because of an
existing medical condition. In conclusion, the creation of
emerging adoptive cell therapies , management of critical
patients suffering from SARS-CoV-2 infection with
maximum efficiency, and, therefore, minimum toxicity
would be needed. Thus, the risk of patient outcomes could
be minimized, and the benefit of those time-consuming

and expensive immunotherapies could be enhanced. This
comprehensive point of view would encourage the usage
of CAR-T cells in the medical intervention of patients
who are infected with SARS-CoV-2, contributing to
the improvement of new immunotherapy techniques
for patients with extreme COVID-19. In conjunction
with other therapeutics to facilitate the advancement of
ubiquitous immunotherapy for COVID-19 would be
promising.
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